Open Journal of Obstetrics and Gynecology

Volume 8, Issue 12 (October 2018)

ISSN Print: 2160-8792   ISSN Online: 2160-8806

Google-based Impact Factor: 0.37  Citations  h5-index & Ranking

Effect of Hyoscine Butyl Bromide on the Course of Labour

HTML  XML Download Download as PDF (Size: 319KB)  PP. 1102-1108  
DOI: 10.4236/ojog.2018.812111    1,337 Downloads   5,823 Views  Citations

ABSTRACT

Background: Hyoscine butyl bromide (Buscopan) is being used as an agent for reducing the duration of labour. There are however conflicting results on the effect of this agent on cervical dilation. Materials and Methods: This was an open label clinical trial of one hundred and thirty two (132) pregnant women in labour. Women were grouped to receive either 20 mg of hyoscine butyl bromide intramuscularly at the onset of active phase labour or placebo “Normal saline”. The main outcome measure was to compare the duration of first stage labour in the study and control groups as well as feto-maternal outcomes. Relevant data were collected using a proforma. The data were analysed using Statistical Package for Social Sciences (SPSS) version 20. Results: A total of 132 were randomised and 123 yielded for analysis. Of these 59 received hyoscine butyl bromide and 64 received placebo. There was no significant difference in the mean duration of active labour to second stage between the drug and placebo arms (312.5 versus 305.3 minutes, respectively, P = 0.788). The feto-maternal outcomes were similar between both arms. Conclusion: Hyoscine butyl bromide does not shorten the duration of labour in spontaneous labour. It also does not change feto-maternal outcomes.

Share and Cite:

Barau, D. , Agida, E. , Onafowokan, O. and Adebayo, F. (2018) Effect of Hyoscine Butyl Bromide on the Course of Labour. Open Journal of Obstetrics and Gynecology, 8, 1102-1108. doi: 10.4236/ojog.2018.812111.

Copyright © 2024 by authors and Scientific Research Publishing Inc.

Creative Commons License

This work and the related PDF file are licensed under a Creative Commons Attribution 4.0 International License.